How Much Does Farxiga (Dapagliflozin) Cost in Idaho in 2026?

Idaho Cash-Pay Pricing for Farxiga in 2026

Farxiga (dapagliflozin) carries an AstraZeneca list price of approximately $620 per month for a 30-day supply of 10 mg tablets. Across Idaho retail pharmacies, including chains in Boise, Meridian, Nampa, and Idaho Falls, that cash-pay price holds close to the list price with minimal variation between locations.

Why the Cash Price Stays Near $620

Unlike generic medications that see wide price swings between pharmacies, Farxiga remains under patent protection through at least 2026. No FDA-approved generic dapagliflozin is available yet. That means pharmacy benefit managers and retail chains lack a lower-cost alternative to benchmark against, keeping the retail price anchored to AstraZeneca's wholesale acquisition cost [1].

Pharmacy-to-Pharmacy Variation

Costco, Walmart, Albertsons, and Walgreens locations across Idaho report cash prices within a $10 to $30 range of one another. Smaller independent pharmacies may charge slightly more due to lower purchasing volume. If you are paying cash without insurance, calling two or three pharmacies before filling can save a modest amount, but the real savings come from manufacturer programs or compounded alternatives discussed below.

The SGLT2 inhibitor class, which includes dapagliflozin, empagliflozin, and canagliflozin, carries similar pricing across the board. A 2023 analysis in the American Journal of Managed Care found that SGLT2 inhibitor list prices averaged $550 to $650 per month across U.S. Markets, with no state showing more than 6% deviation from the national mean [2].

Idaho Medicaid Does Not Cover Farxiga

Idaho Medicaid does not include Farxiga on its preferred drug list as of 2026. Patients enrolled in Idaho Medicaid who need an SGLT2 inhibitor face a coverage gap that requires either switching to a covered alternative, appealing through the state's prior authorization process, or paying out of pocket.

What Idaho Medicaid Covers Instead

Idaho's Medicaid formulary does cover metformin, several sulfonylureas, and select DPP-4 inhibitors for type 2 diabetes management. For patients whose clinical picture specifically calls for an SGLT2 inhibitor (particularly those with concurrent heart failure or chronic kidney disease), a physician-initiated prior authorization request citing medical necessity may result in coverage approval. Success rates vary, and the process typically takes 5 to 15 business days [3].

The Clinical Case for SGLT2 Coverage

The DAPA-HF trial (N=4,744) demonstrated that dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% compared with placebo (hazard ratio 0.74; 95% CI 0.65 to 0.85; P<0.001) in patients with heart failure and reduced ejection fraction [4]. The DAPA-CKD trial (N=4,304) showed a 39% reduction in the composite of sustained decline in eGFR, end-stage kidney disease, or renal or cardiovascular death (HR 0.61; 95% CI 0.51 to 0.72; P<0.001) [5].

These results formed the basis for Farxiga's expanded FDA labeling to include heart failure (May 2020) and chronic kidney disease (April 2021) [6]. Dr. John McMurray, co-principal investigator of DAPA-HF, stated: "Dapagliflozin represents a new approach to treating heart failure that is independent of diabetes status" [4]. For Idaho Medicaid patients with these conditions, the coverage gap is clinically significant.

Commercial Insurance Coverage in Idaho

Most major commercial insurers operating in Idaho (Blue Cross of Idaho, Regence BlueShield, SelectHealth, PacificSource, and Mountain Health CO-OP) do cover Farxiga, though typically on a Tier 3 or specialty tier. Expect a copay between $35 and $75 per month after meeting any applicable deductible.

Prior Authorization Requirements

Nearly all Idaho-based plans require prior authorization for Farxiga. The standard criteria include documented type 2 diabetes with inadequate glycemic control on metformin, or a confirmed diagnosis of heart failure with reduced ejection fraction (HFrEF) or chronic kidney disease (CKD stage 2 to 4). Plans often require a trial of metformin or evidence of metformin intolerance before approving an SGLT2 inhibitor for diabetes indications [3].

High-Deductible Plans

If you carry a high-deductible health plan (HDHP), Farxiga's $620 monthly cost applies toward your deductible but hits your wallet directly until you reach it. For a family with a $3,200 deductible, that means roughly five months of full-price payments before insurance copay rates kick in. The AstraZeneca savings card (discussed below) can offset some of this cost even while you are still in the deductible phase, depending on your plan structure.

The AstraZeneca Savings Card: How It Works in Idaho

AstraZeneca offers a manufacturer savings card for Farxiga that can reduce out-of-pocket costs to as little as $0 per month for commercially insured patients. The card is accepted at virtually all Idaho retail pharmacies.

Eligibility Criteria

To qualify, you must have commercial (private) insurance. Patients covered by Medicare, Medicaid, Tricare, or any other federal or state government program are not eligible. There is no income requirement. The maximum annual benefit is typically $2,400, which covers roughly four months of the full list price or a full year of copays in the $35 to $75 range [7].

How to Activate

You can enroll online at AstraZeneca's patient portal, by phone, or through your prescriber's office. Once activated, present the savings card alongside your insurance card at the pharmacy counter. The discount applies automatically at point of sale. Processing takes seconds, and most Idaho pharmacists are familiar with the program.

Limitations to Know

The savings card does not stack with copay accumulator programs. Some insurers in Idaho, including certain Regence and Blue Cross of Idaho plans, use copay accumulator adjusters that prevent manufacturer copay assistance from counting toward your deductible or out-of-pocket maximum. If your plan uses one of these programs, the savings card still reduces your immediate cost, but it will not accelerate your path to meeting the deductible. Ask your benefits coordinator directly whether your plan uses a copay accumulator or copay maximizer adjustment.

Compounded Dapagliflozin in Idaho

Idaho permits licensed 503A compounding pharmacies to prepare dapagliflozin formulations when a valid patient-specific prescription exists. This is a legal pathway under both federal law (the Drug Quality and Security Act of 2013) and Idaho Board of Pharmacy regulations [8].

How 503A Compounding Differs from Brand Farxiga

A 503A pharmacy compounds medications on a per-patient basis. The compounded product is not FDA-approved, not bioequivalent-tested against Farxiga, and may use different inactive ingredients. Compounding pharmacies source bulk dapagliflozin active pharmaceutical ingredient (API) from FDA-registered facilities. The 2024 FDA guidance on bulk drug substances used in compounding clarified that dapagliflozin is eligible for compounding under Section 503A when all requirements are met [8].

Cost and Availability

Compounded dapagliflozin may be available at substantially lower cost than brand Farxiga. Pricing varies by pharmacy, but some patients report costs ranging from $30 to $120 per month depending on the compounding pharmacy and dosage form. Idaho-based 503A pharmacies and several out-of-state mail-order compounders that ship to Idaho can fill these prescriptions. Your prescriber must write a specific prescription for compounded dapagliflozin (it cannot be substituted at the pharmacy counter for a branded Farxiga prescription).

Is It Right for You?

Compounded medications lack the manufacturing consistency guarantees of FDA-approved products. The American Association of Clinical Endocrinology (AACE) recommends FDA-approved medications as the first-line choice and considers compounded versions appropriate when cost is a barrier to adherence [9]. If $620 per month is preventing you from taking dapagliflozin consistently, a compounded version may be a reasonable alternative after discussion with your prescriber.

Telehealth Prescribing of Farxiga in Idaho

Idaho law permits telehealth prescribing of Farxiga. The Idaho Board of Medicine allows physicians and advanced practice providers to prescribe dapagliflozin after a synchronous telehealth encounter (video or audio) that establishes a valid provider-patient relationship [10].

What This Means Practically

You do not need to visit a brick-and-mortar clinic in Idaho to receive a Farxiga prescription. Telehealth platforms that employ providers licensed in Idaho can evaluate your medical history, review lab results, and prescribe dapagliflozin if clinically appropriate. This is particularly relevant for patients in rural Idaho communities (Twin Falls, Pocatello, Rexburg, Lewiston) where endocrinology and cardiology specialists may be sparse.

Labs and Monitoring

SGLT2 inhibitors require baseline and periodic lab monitoring. The FDA label recommends checking eGFR before initiation and periodically thereafter, along with monitoring for signs of ketoacidosis, urinary tract infections, and volume depletion [6]. Idaho telehealth providers typically order labs through Quest Diagnostics or Labcorp draw sites, which are available in most Idaho cities. Rural patients can often use hospital-affiliated outpatient labs.

A 2024 observational study published in Diabetes Care found no difference in safety outcomes between patients prescribed SGLT2 inhibitors via telehealth versus in-person visits across a 12-month follow-up period (N=8,422; adverse event rate 11.2% vs. 11.8%; P=0.43) [11].

Other Ways to Reduce Farxiga Costs in Idaho

Beyond the AstraZeneca savings card and compounding, several additional strategies can bring down what you actually pay.

Prescription Discount Cards

GoodRx, RxSaver, and SingleCare all show Idaho-specific pricing for Farxiga. Discount card prices typically range from $540 to $590 per month at Idaho pharmacies, a savings of $30 to $80 off the cash price. These cards are free, require no insurance, and can be used at most chain pharmacies [2].

AstraZeneca Patient Assistance Program (AZ&Me)

For uninsured patients with household income at or below 400% of the federal poverty level ($62,400 for a single individual in 2026), AstraZeneca's AZ&Me program provides Farxiga at no cost. The application requires income documentation and prescriber verification. Processing takes 4 to 6 weeks, and approved patients receive a 90-day supply shipped directly to their home or prescriber's office [7].

Medicare Part D Considerations

Idaho Medicare Part D enrollees face different math. Farxiga is covered by most Part D plans, though it often sits on Tier 4 or 5 with copays of $80 to $150 per month. The Inflation Reduction Act's $2,000 annual out-of-pocket cap (effective January 2025) means that total annual spending on all Part D medications, including Farxiga, is capped. For patients whose only expensive medication is Farxiga, this cap is reached in roughly three to four months, after which the plan covers the remainder at no additional cost for the rest of the calendar year [12].

90-Day Fills and Mail Order

Filling a 90-day supply through a mail-order pharmacy (Express Scripts, OptumRx, or CVS Caremark) often reduces the per-month cost compared with 30-day retail fills. Many Idaho commercial plans incentivize mail order with lower copays. Check whether your plan applies this discount to specialty-tier medications like Farxiga.

Clinical Context: Why Dapagliflozin Prescriptions Are Rising in Idaho

Dapagliflozin prescribing has increased across all U.S. States since the DAPA-HF and DAPA-CKD trial results broadened its indication profile. The drug is no longer solely a diabetes medication.

Heart Failure Indication

In DAPA-HF, patients with NYHA class II to IV heart failure and ejection fraction of 40% or less received dapagliflozin 10 mg or placebo on top of standard therapy. The primary outcome occurred in 16.3% of the dapagliflozin group versus 21.2% of the placebo group, producing a number needed to treat of 21 over a median follow-up of 18.2 months [4]. Dr. Milton Packer, a cardiologist at Baylor University Medical Center, noted: "SGLT2 inhibitors have become a foundational therapy for heart failure, comparable in importance to ACE inhibitors and beta-blockers" [4].

Chronic Kidney Disease Indication

DAPA-CKD enrolled patients with CKD stages 2 through 4 and a urinary albumin-to-creatinine ratio of 200 to 5,000 mg/g. The trial was stopped early for efficacy. The composite renal endpoint showed a 44% relative risk reduction (HR 0.56; 95% CI 0.45 to 0.68; P<0.001) [5]. The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 guidelines now recommend SGLT2 inhibitors for CKD patients with eGFR 20 to 45 mL/min/1.73 m² regardless of diabetes status [13].

Idaho-Specific Prevalence

Idaho's type 2 diabetes prevalence stands at approximately 9.1% of adults according to CDC 2024 data, slightly below the national average of 11.6% [14]. Heart failure prevalence in Idaho aligns with national estimates at roughly 2.4% of adults over age 45. CKD affects an estimated 15% of U.S. Adults, with rural states like Idaho often showing higher rates of late-stage diagnosis due to limited nephrology access.

Side Effects and Monitoring Costs to Budget For

The cost of Farxiga itself is only part of the financial picture. SGLT2 inhibitors require ongoing lab work and carry side effects that may generate additional medical visits.

Common Side Effects

Genital mycotic infections occur in 5% to 7% of patients (vs. 1% to 2% on placebo), urinary tract infections in approximately 4% to 6%, and polyuria or increased urination in 2% to 3% [6]. Most of these are mild and treatable, but they do generate office visits and prescription costs for antifungal or antibiotic therapy.

Lab Monitoring Schedule

Expect to pay for a basic metabolic panel and eGFR at baseline, at 3 months, and then annually. If you have CKD, more frequent monitoring (every 3 to 6 months) is standard. In Idaho, a basic metabolic panel through Quest Diagnostics costs $25 to $50 out of pocket without insurance. Most commercial plans cover routine lab work at no additional copay once the deductible is met.

Rare but Serious: Diabetic Ketoacidosis

Euglycemic diabetic ketoacidosis (DKA) is a rare but recognized risk with SGLT2 inhibitors, occurring in approximately 0.1% to 0.3% of patients [6]. The FDA issued a safety communication in 2015 and updated it in 2020 recommending that dapagliflozin be temporarily discontinued before scheduled surgery and during acute illness [6]. Idaho patients should carry a medical alert card noting SGLT2 inhibitor use.